Ticker >

Fredun Pharma share price

Fredun Pharmaceuticals Ltd.

BSE: 539730 SECTOR: Pharmaceuticals & Drugs  14k   40   4

724.00
+5.25 (0.73%)
BSE: 01 Nov 07:01 PM

Price Summary

Today's High

₹ 729.9

Today's Low

₹ 702

52 Week High

₹ 1054

52 Week Low

₹ 650

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

341.85 Cr.

Enterprise Value

424.94 Cr.

No. of Shares

0.47 Cr.

P/E

19.33

P/B

2.61

Face Value

₹ 10

Div. Yield

0.1 %

Book Value (TTM)

₹  277.17

CASH

3.44 Cr.

DEBT

86.52 Cr.

Promoter Holding

49.17 %

EPS (TTM)

₹  37.46

Sales Growth

22.37%

ROE

13.86 %

ROCE

18.35%

Profit Growth

70.58 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Fredun Pharmaceuticals Ltd.

MAMALAIT GRANULES FREDCAL BIRD AND BEAUTY PURI5 FREPREIMECAL FREOSSITONE GRANULES FREOSSIPOWER

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year22.37%
3 Year34.55%
5 Year35.77%

Profit Growth

1 Year70.58%
3 Year78.44%
5 Year43.91%

ROE%

1 Year13.86%
3 Year10.02%
5 Year9.88%

ROCE %

1 Year18.35%
3 Year13.68%
5 Year14.39%

Debt/Equity

0.9827

Price to Cash Flow

-23.72

Interest Cover Ratio

2.6912666750384

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2024 49.17 0.00
Mar 2024 49.13 0.00
Dec 2023 49.16 0.00
Sep 2023 49.31 0.00
Jun 2023 49.62 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 78.442815056389% for the Past 3 years.
  • The company has shown a good revenue growth of 34.5465192933731% for the Past 3 years.
  • Company’s PEG ratio is 0.289194196552267.
  • Company has a healthy liquidity position with current ratio of 2.03650165115977.

 Limitations

  • Company has negative cash flow from operations of -14.4088.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 81.99 87.01 118.03 78.81 107.35
Total Expenditure 72.38 76.49 106.87 68.33 93.4
Operating Profit 9.61 10.52 11.17 10.48 13.95
Other Income 0 0 0 0 0
Interest 2.9 3.77 4.37 3.91 5.31
Depreciation 0.94 0.99 0.96 1.05 1.06
Exceptional Items 0 0 0 0 0
Profit Before Tax 5.77 5.76 5.84 5.52 7.58
Tax 1.83 1.54 0.78 1.39 3.3
Profit After Tax 3.94 4.22 5.06 4.13 4.27
Adjusted EPS (Rs) 8.41 8.98 10.77 8.79 9.05

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 97.02 112.77 133.89 224.46 274.68
Total Expenditure 86.99 104.44 124.55 210.55 245.85
Operating Profit 10.03 8.33 9.35 13.91 28.83
Other Income 0.58 0.52 1.4 1.63 1.84
Interest 3.12 4.47 4.37 4.78 10.35
Depreciation 1.33 1.88 2 2.16 2.81
Exceptional Items 0 0 -1.16 0 0
Profit Before Tax 6.16 2.49 3.21 8.6 17.51
Tax 1.7 0.59 1.19 2.26 6.7
Net Profit 4.46 1.9 2.01 6.34 10.81
Adjusted EPS (Rs.) 11.18 4.77 5.05 14.29 23.84

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 3.99 3.99 3.99 4.43 4.53
Total Reserves 35 37.33 39.08 63.63 91.84
Borrowings 10.64 11.5 29.11 42.04 48.93
Other N/C liabilities 1.88 2.57 2.98 3.14 5.81
Current liabilities 53.41 85.99 86.46 73.75 106.17
Total Liabilities 104.91 141.38 161.62 186.99 257.28
Assets
Net Block 31.35 30.97 30.35 32.34 38.93
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 1.03 1.08 1.18 2 2.13
Other N/C Assets 0 0 0 0 0
Current Assets 72.52 109.32 130.08 152.65 216.21
Total Assets 104.91 141.38 161.62 186.99 257.28
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 6.18 2.35 2.01 8.58 17.46
Adjustment 2.08 6.03 8.65 7.82 11.7
Changes in Assets & Liabilities -7.43 -19.02 -10.5 -18.77 -43.57
Tax Paid 0 0 0 0 0
Operating Cash Flow 0.84 -10.64 0.17 -2.38 -14.41
Investing Cash Flow -5.25 -1.49 -1.39 -4.14 -9.4
Financing Cash Flow 4.43 13.73 -0.71 7.47 25.18
Net Cash Flow 0.01 1.59 -1.93 0.94 1.36

Corporate Actions

Investors Details

PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
promoters 49.62 49.31 49.16 49.13 49.17
daulat nariman medhora 30.41 30.12 30.02 30.01 30.02
fredun nariman medhora 3.50 3.83 3.81 3.81 3.82
nariman medhora 15.72 15.37 15.32 15.31 15.32
PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
investors 50.38 50.69 50.84 50.87 50.83
arun kumar mukherjee 1.21 1.45 1.44 1.44 1.70
bank of india 1.64 1.60 1.60 1.60 1.60
llp 0.02 0.46 0.45 0.46 0.49
nikhil kishorchandra vora... 6.82 6.58 6.50 6.50 6.41

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

  • PresentationQ3FY23 1 Mar 2023
  • PresentationQ3FY22 23 Feb 2022

Company News

Fredun Pharma - Quaterly Results26 Oct 2024, 9:40PM Fredun Pharma - Quaterly Results29 Jul 2024, 7:32PM Fredun Pharma - Quaterly Results29 Jul 2024, 7:32PM Fredun Pharma - Quaterly Results7 May 2024, 10:10PM Fredun Pharma - Quaterly Results7 May 2024, 10:10PM Fredun Pharma - Quaterly Results14 Feb 2024, 7:24PM Fredun Pharma - Quaterly Results14 Feb 2024, 7:24PM Fredun Pharmaceuticals informs about press release 12 Feb 2024, 1:29PM Fredun Pharmaceuticals gets orders worth Rs 28 crore from SEA countries12 Feb 2024, 12:41PM Fredun Pharmaceuticals informs about voting results of EGM 19 Jan 2024, 5:16PM Fredun Pharmaceuticals informs about loss of original share certificates17 Jan 2024, 3:24PM Fredun Pharmaceuticals informs about board meeting9 Dec 2023, 2:37PM Fredun Pharmaceuticals informs about outcome of board meeting2 Aug 2023, 5:10PM Fredun Pharmaceuticals informs about press release21 Jul 2023, 5:08PM Fredun Pharma - Quaterly Results19 Jul 2023, 6:15PM Fredun Pharma - Quaterly Results19 Jul 2023, 6:15PM Fredun Pharma - Quaterly Results19 Jul 2023, 6:15PM Fredun Pharmaceuticals informs about outcome of board meeting 25 May 2023, 9:46AM Fredun Pharmaceuticals informs about revised outcome of board meeting 3 May 2023, 3:12PM Fredun Pharmaceuticals informs about outcome of board meeting 28 Jan 2023, 11:50AM Fredun Pharma - Quaterly Results27 Jan 2023, 8:10PM Fredun Pharma - Quaterly Results27 Jan 2023, 8:10PM Fredun Pharmaceuticals informs about certificate3 Jan 2023, 3:07PM Fredun Pharmaceuticals informs about change in registered office address13 Dec 2022, 3:07PM Fredun Pharmaceuticals informs about press release 28 Nov 2022, 5:17PM Fredun Pharmaceuticals bags two contracts for Pharma and DC Granules28 Nov 2022, 4:42PM Fredun Pharma - Quaterly Results10 Nov 2022, 7:43PM Fredun Pharma - Quaterly Results10 Nov 2022, 7:43PM Fredun Pharma - Quaterly Results16 May 2022, 7:00PM Fredun Pharma - Quaterly Results16 May 2022, 7:00PM Fredun Pharmaceuticals informs about board meeting9 May 2022, 10:13AM Fredun Pharmaceuticals gets nod to manufacture Xenografts 15 Mar 2022, 10:11AM Fredun Pharma - Quaterly Results6 Nov 2021, 4:30PM Fredun Pharma - Quaterly Results6 Nov 2021, 4:30PM Fredun Pharma - Quaterly Results6 Nov 2021, 4:30PM Fredun Pharmaceuticals informs about confirmation certificate4 Oct 2021, 3:40PM Fredun Pharmaceuticals informs about issue of securities15 Sep 2021, 5:18PM Fredun Pharmaceuticals bags order worth Rs 22 crore15 Sep 2021, 9:16AM Fredun Pharmaceuticals informs about annual report 6 Sep 2021, 3:55PM Fredun Pharmaceuticals wins ‘India’s Most Admirable Brand’ award24 Aug 2021, 10:35AM Fredun Pharmaceuticals informs about closure of trading window1 Jul 2021, 1:00PM Fredun Pharmaceuticals informs about outcome of board meeting 29 Jun 2021, 1:00PM Fredun Pharmaceuticals board recommends final dividend29 Jun 2021, 12:54PM Fredun Pharmaceuticals informs about annual secretarial compliance report24 Jun 2021, 11:45AM Fredun Pharmaceuticals informs about board meeting19 Jun 2021, 3:27PM Fredun Pharmaceuticals informs about board meeting19 Jun 2021, 3:08PM Fredun Pharmaceuticals informs about newspaper publication16 Feb 2021, 11:17AM Fredun Pharmaceuticals informs about press release5 Sep 2020, 11:47AM Fredun Pharmaceuticals informs about AGM27 Aug 2020, 5:09PM

Fredun Pharma Stock Price Analysis and Quick Research Report. Is Fredun Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Fredun Pharma and its performance over the period of time. Fredun Pharma stock price today is Rs 724.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Fredun Pharma cash from the operating activity was Rs -14.4088 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Fredun Pharma has a Debt to Equity ratio of 0.9827 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Fredun Pharma , the EPS growth was 66.8252580024488 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Fredun Pharma has OPM of 10.4947072109791 % which is a bad sign for profitability.
     
  • ROE: Fredun Pharma have a average ROE of 13.8637779198945 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Fredun Pharma is Rs 724. One can use valuation calculators of ticker to know if Fredun Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Fredun Pharma
X